

<https://helda.helsinki.fi>

---

## Fluid challenges in intensive care : the FENICE study A global inception cohort study

Cecconi, Maurizio

2015-09

---

Cecconi , M , Hofer , C , Teboul , J-L , Pettila , V , Wilkman , E , Molnar , Z , Della Rocca , G , Aldecoa , C , Artigas , A , Jog , S , Sander , M , Spies , C , Lefrant , J-Y , De Backer , D , FENICE Investigators & ESICM Trial Grp 2015 , ' Fluid challenges in intensive care : the FENICE study A global inception cohort study ' , Intensive Care Medicine , vol. 41 , no. 9 , pp. 1529-1537 . <https://doi.org/10.1007/s00134-015-3850-x>

---

<http://hdl.handle.net/10138/337051>

<https://doi.org/10.1007/s00134-015-3850-x>

---

cc\_by\_nc

publishedVersion

---

*Downloaded from Helda, University of Helsinki institutional repository.*

*This is an electronic reprint of the original article.*

*This reprint may differ from the original in pagination and typographic detail.*

*Please cite the original version.*



**Maurizio Cecconi**  
**Christoph Hofer**  
**Jean-Louis Teboul**  
**Ville Pettila**  
**Erika Wilkman**  
**Zsolt Molnar**  
**Giorgio Della Rocca**  
**Cesar Aldecoa**  
**Antonio Artigas**  
**Sameer Jog**  
**Michael Sander**  
**Claudia Spies**  
**Jean-Yves Lefrant**  
**Daniel De Backer**  
on behalf of the FENICE Investigators  
and the ESICM Trial Group

# Fluid challenges in intensive care: the FENICE study

## A global inception cohort study

Received: 16 March 2015  
Accepted: 27 April 2015  
Published online: 11 July 2015  
© The Author(s) 2015. This article is published with open access at Springerlink.com

### Electronic supplementary material

The online version of this article (doi:10.1007/s00134-015-3850-x) contains supplementary material, which is available to authorized users.

The FENICE investigators are listed in full in ESM 2 (National Coordinators) and ESM 4 (Steering Committee, Study Statistician, Study Coordinator and Local Investigators).

Trial registration: ClinicalTrials.Gov  
NCT01787071.

Zurich, Birmensdorferstrasse 497, 8063  
Zurich, Switzerland

J.-L. Teboul  
Hôpitaux universitaires Paris-Sud, Hôpital  
de Bicêtre, Service de réanimation  
médicale, 78, rue du Général Leclerc, 94270  
Le Kremlin-Bicêtre, France

J.-L. Teboul  
Faculté de médecine Paris-Sud, EA4533,  
University Paris-Sud, 63, rue Gabriel Péri,  
94270 Le Kremlin-Bicêtre, France

V. Pettila · E. Wilkman  
Intensive Care Units, Department of  
Anesthesiology, Intensive Care Medicine  
and Pain Medicine, Helsinki University  
Hospital, Helsinki, Finland

Z. Molnar  
Department of Anaesthesiology and  
Intensive Therapy, University of Szeged,  
Szeged, Hungary

G. Della Rocca  
Department of Anesthesia and Intensive  
Care Medicine, University Hospital,  
Medical School, University of Udine, P.le  
S. Maria della Misericordia, 33100 Udine,  
Italy

C. Aldecoa  
Department of Anesthesiology and Surgical  
Critical Care, Hospital Universitario Río  
Hortega, Valladolid, Spain

A. Artigas  
Critical Care Center, CIBER Enfermedades  
Respiratorias, Sabadell Hospital,  
Corporació Sanitaria Universitaria Parc  
Tauli, Autonomous University of  
Barcelona, Barcelona, Spain

S. Jog  
Deenanath Mangeshkar Hospital and  
Research Center, Pune 411004, India

M. Sander · C. Spies  
Department of Anesthesiology and  
Intensive Care Medicine, Charité University  
Medicine Berlin, Charité Campus Mitte,  
Campus Virchow Klinikum, Charitéplatz 1,  
10117 Berlin, Germany

J.-Y. Lefrant  
Service des Réanimations, CHU Nîmes,  
Place du Professeur Robert Debré, 30029  
Nîmes cedex 9, France

D. De Backer  
Department of Intensive Care, Erasme  
University Hospital, Université Libre de  
Bruxelles, Brussels, Belgium

D. De Backer  
Department of Intensive Care, CHIREC  
Hospitals, Brussels, Belgium

M. Cecconi (✉) · on behalf of the FENICE  
Investigators and the ESICM Trial Group  
Anaesthesia and Intensive Care, St George's  
Hospital and Medical School, London  
SW17 0QT, UK  
e-mail: mcecconi@sgul.ac.uk  
Tel.: 00442087253295

C. Hofer  
Institute of Anaesthesiology and Intensive  
Care Medicine, Triemli City Hospital

**Abstract Background:** Fluid challenges (FCs) are one of the most commonly used therapies in critically ill patients and represent the cornerstone of hemodynamic management

in intensive care units. There are clear benefits and harms from fluid therapy. Limited data on the indication, type, amount and rate of an FC in critically ill patients exist in the literature. The primary aim was to evaluate how physicians conduct FCs in terms of type, volume, and rate of given fluid; the secondary aim was to evaluate variables used to trigger an FC and to compare the proportion of patients receiving further fluid administration based on the response to the FC.

**Methods:** This was an observational study conducted in ICUs around the world. Each participating unit entered a maximum of 20 patients with one

FC. **Results:** 2213 patients were enrolled and analyzed in the study. The median [interquartile range] amount of fluid given during an FC was 500 ml (500–1000). The median time was 24 min (40–60 min), and the median rate of FC was 1000 [500–1333] ml/h. The main indication for FC was hypotension in 1211 (59 %, CI 57–61 %). In 43 % (CI 41–45 %) of the cases no hemodynamic variable was used. Static markers of preload were used in 785 of 2213 cases (36 %, CI 34–37 %). Dynamic indices of preload responsiveness were used in 483 of 2213 cases (22 %, CI 20–24 %). No safety

variable for the FC was used in 72 % (CI 70–74 %) of the cases. There was no statistically significant difference in the proportion of patients who received further fluids after the FC between those with a positive, with an uncertain or with a negatively judged response. **Conclusions:** The current practice and evaluation of FC in critically ill patients are highly variable. Prediction of fluid responsiveness is not used routinely, safety limits are rarely used, and information from previous failed FCs is not always taken into account.

## Introduction

Many liters of intravenous fluids are used per year to treat critically ill patients worldwide. Fluids are one of the most commonly used therapies in critically ill patients and represent the cornerstone of hemodynamic management in intensive care units (ICUs) [1]. The basic physiological target of administration of fluids is to improve tissue perfusion. Hemodynamic optimization with fluids has been shown to improve patient outcome when applied in the perioperative period and in the early phases of sepsis [1–4]. Timing of the intervention is important; in the context of shock, higher fluid administration in the first 3 h was associated with better outcome in a retrospective study [5]. On the other hand, liberal administration of fluids may lead to a positive fluid balance [6] which is independently associated with a poor outcome [7]. Accordingly, in patients with respiratory failure, once hemodynamically stable, fluid restriction is associated with earlier weaning from mechanical ventilation [8].

Altogether, it seems reasonable to give the needed amount of fluids when hemodynamically patients are unstable and to restrict fluids when they are stabilized. Such an approach makes physiological sense and in theory should bring better outcomes to the patients. Whereas in overt bleeding, fluids are often given without guidance with specific hemodynamic monitoring, in other conditions, when hypovolemia may be subtler or when the response to fluids is more variable, fluids may be given on the basis of monitoring their hemodynamic impact. This practice, the “fluid challenge” technique (FC) was proposed more than 30 years ago [9–11]. Over recent decades new techniques have been developed in order to monitor and predict the response to fluids. The roles of static markers of preload such as central venous pressure (CVP) and pulmonary artery occlusion pressure (PAOP)

have been questioned and dynamic indices of preload have been studied [12–14]. The use of dynamic indices is now recommended [4] but many technical limitations may preclude their use.

However, no data exist on the manner in which FCs are indicated and performed in critically ill patients around the globe. We conducted a multicenter international observational study aiming to evaluate the indications, current practice, and judgment of benefit of FCs in critical care settings. We hypothesized that there is an extensive variation in the current practice of FC.

## Methods

This was an observational study conducted by the ESICM Trials Group (17–23 April 2013 or 23–29 May 2013) and registered on ClinicalTrials.gov (NCT01787071). ICUs were able to enter the study in one of the 2 weeks. The possibility to choose between 2 weeks was chosen in order to compensate for differences in national holidays in different countries and therefore to maximize the recruitment of study units. IRB approval was obtained in each country and the local investigators were responsible to ensure that with local and national requirements were fulfilled. In most participating countries informed consent from the patient was waived owing to the observational study design. National coordinators and local investigators are listed in the electronic supplementary material (ESM).

We included all consecutive adult (18 years old and above) patients, up to a maximum of 20 per participating unit, in whom an FC was performed during a 1-week period. FC was defined as administration of any bolus of fluid (crystalloid or colloid) in less than 2 h. Administration of red blood cells or fresh frozen plasma was not considered as

an FC. The exclusion criteria were previous inclusion in the study, overt bleeding, and time of an FC exceeding 120 min. Only one FC, ideally the first, was considered for each patient. Only one FC per patient was recorded.

We collected data on patient demographics, indications for the FC, the type, amount, and rate of fluids administered, available hemodynamic variables, and judgment on the efficacy and safety of the FC. The case report form (CRF) is available in the ESM. Anonymous CRF data were uploaded by local investigators using a Web-based electronic CRF (Clinfile, Sevres, France). The data were stored securely in a server located in Brussels. All procedures regarding data management complied with the EU directive on data protection (95/46/EC).

## Study aims

The primary aim of this study was to evaluate how physicians indicate FC.

The secondary aims were

- to evaluate the type, volume, and rate of fluid administered during an FC.
- to evaluate variables used to trigger/indicate an FC, and to judge the effect or safety of an FC.
- to compare the proportion of patients receiving further fluid administration based on the response to the fluid challenge, as judged by the bedside clinician after a fluid challenge.

## Statistical analysis

Categorical variables are described as numbers (percentages) and continuous variables as mean ( $\pm$ standard deviation), if normally distributed, or median [interquartile range] if not normally distributed. The paired *t* test or Wilcoxon test was used to compare hemodynamic variables after the FC with baseline, when applicable. Proportions of patients were compared with  $\chi^2$  test and data presented as proportions and odd ratios. A *p* value of less than 0.05 was considered statistically significant. We targeted a minimum of 100 study sites with a maximum of 20 FCs each and a minimum of 1000 patients.

## Results

We included 2279 patients with an FC from 311 centers across 46 countries (ESM). Of those 2279, 66 patients were excluded from the analysis as a result of at least one exclusion criterion (see the study flow chart, Fig. 1 ESM). A total of 2213 patients were analyzed.

Data on demographic factors and concomitant treatment are presented in Table 1. The main diagnostic groups were sepsis ( $n = 595$ , 27.0 % [CI 25.2–28.9 %]), cardiac ( $n = 454$ , 20.6 % [CI 18.9–22.3 %]), and respiratory failure ( $n = 238$ , 10.8 % [CI 9.5–12.1 %]).

The median amount of fluid given during an FC was 500 ml [500–1000]. The median time was 24 min [40–60 min], and the median rate of fluid administration was 1000 [500–1333] ml/h. Crystalloids were the most used (in 74.0 % [CI 72.2–75.8 %] of the cases) including normal saline in 45.9 % [CI 25.2–28.9 %], and balanced solutions were used in 53.5 % [CI 51.4–55.6 %] of FCs (Table 2).

The main indication for fluid administration was hypotension in 1211 (58.7 % [CI 56.7–60.1 %]) of FCs. In 42.7 % [CI 40.6–44.8 %] of the cases no hemodynamic variable was used to predict fluid responsiveness. Static markers of preload were used in 785 of 2213 cases (35.5 % [CI 33.5–37.5 %]). In 572 of 785 of these cases (89.9 % [CI 87.8–92.0 %]) CVP was the leading variable used (25.8 % [CI 24.0–27.6 %] of all FCs). Dynamic indices of preload responsiveness were used in 483 of 2213 cases (21.9 % [CI 20.2–23.6 %]). In 238 of those 483 cases (49.3 % [CI 44.8–53.8 %]) passive leg raising (PLR) was the leading variable (10.7 % [CI 9.4–12.0 %] of all FCs) (Table 3).

The response to fluid administration was judged as positive in 1544 of 2213 (69.8 % [CI 67.9–71.7 %]) of the FCs, most often as an increase in arterial blood pressure (1039 of 1544, 67.3 % [CI 65.0–69.7 %]). No safety variable for the FC was used in 72.0 % [CI 70.1–73.9 %] of the cases. When used, CVP was the most common variable (57 %). Further fluids were administered in 1050 of 2213 (49.8 % [CI 47.7–51.9 %]) of the cases. The proportion of patients who received further fluids after was similar in patients with a positive ( $47.9 \pm 2.5$  %), with an uncertain [ $52.4 \pm 7.1$  %, OR 0.94 (0.76–1.16)] or with a negatively judged response to FC [ $49.4 \pm 6.6$  %, OR 0.83 (0.62–1.13)] ( $p = 0.46$  by  $\chi^2$  test) (Fig. 1).

## Discussion

The two major findings of this large global multicenter observational study comprising 2213 patients are first a significant variability in the conduction of FC and second the fact that the response to the initial FC does not have an impact when prescribing further fluid administration. These findings were observed in critically ill patients all around the world. All aspects of the FC, the type, volume, and rate of given fluids, and more importantly the indication, evaluation of possible benefit, and safety variables used varied significantly. It is possible that some of the

**Table 1** Baseline characteristics and concomitant treatments in critically ill patients (*N* = 2213)

Age (years)	63 ± 16
Female sex	824 (37.3 [35.3–39.3])
Reason for admission to ICU [ <i>n</i> (%)]	
Medical	962 (43.5 [41.4–45.6])
Surgical	691 (31.2 [29.3–33.1])
Emergency surgical	548 (24.8 [23.0–26.6])
Main diagnosis	
Sepsis	595 (27.0 [25.2–28.9])
Cardiac	454 (20.6 [18.9–22.3])
Respiratory	238 (10.8 [9.5–12.1])
Neurologic	180 (8.2 [7.1–9.3])
Trauma	141 (6.4 [5.4–7.4])
Intoxication	41 (1.9 [1.3–2.5])
Other	558 (25.3 [23.5–27.1])
SOFA score	7 [4–10]
Physiological variables	
HR (bpm)	95 ± 24
MAP (mmHg)	70 ± 16
CVP (mmHg)	8 ± 5
Urine output (ml/h)	40 [20–80]
Fluid balance previous 24 h (ml)	2698 [1500–3945]
Lactate (mmol/L)	1.8 [1.1–2.9]
Vasopressor/inotropic agents	
Dopamine ( <i>n</i> (%); µg/kg min)	91 (4); 5 [4–10]
Norepinephrine ( <i>n</i> (%); µg/kg min)	903 (41); 0.16 [0.07–0.34]
Epinephrine ( <i>n</i> (%); µg/kg min)	74 (3); 0.1 [0.03–0.30]
Dobutamine ( <i>n</i> (%); µg/kg min)	159 (7); 4 [3–5]
Mechanical ventilation, <i>n</i> (%) of 2172	
None	736 (33.8 [31.8–35.8])
Noninvasive ventilation	64 (2.9 [2.2–3.6])
Invasive mechanical ventilation	1372 (63.1 [61.1–65.1])
Characteristics of patients under invasive mechanical ventilation <i>n</i> (%) of 1372	
Sedation present	927 (67.6 [65.1–70.1])
Spontaneous ventilation included	602 (43.8 [41.2–46.4])
Renal replacement therapy, <i>n</i> (%) of 2087	
None	1930 (92.5 [91.4–93.6])
Dialysis	58 (2.8 [2.1–3.5])
Hemofiltration	99 (4.7 [3.8–5.6])

Qualitative data are given as absolute number (percentage); quantitative data are given as median value [interquartile range]

HR heart rate, MAP mean arterial pressure, CVP central venous pressure, CVVH continuous veno-venous hemofiltration

variability may be explained by variables not collected in our study, such as unit policies and protocols.

While we recorded only one FC per patient, we also recorded the decision for further fluid administration post FC. When looking at the response to fluid administration, investigators found a positive response only in seven cases out of ten. However, further fluids were given in comparable proportions of patients despite the initial response. If an FC is used to look at a dynamic response and to decide whether further fluids may be administered safely, one would expect that further fluids should be administered only in patients with a positive initial response. In our study the response to the initial fluid challenge made no difference to the decision for further fluid administration. This behavior seems to be harmful and highlights a huge need for education.

This huge variability in the current practice regarding an FC may reflect the presence of controversies in current guidelines. In the Surviving Sepsis Guidelines fluids are

recommended in the very early phase of hemodynamic resuscitation of patients with severe sepsis [15]. In this case a fluid bolus is considered as administration of fluids of 30 ml/kg. In high-risk surgical patients fluid challenges are often given in smaller amounts [11]. In the perioperative setting there are guidelines covering the administration of fluids recommending the use of fluids for stroke volume optimization [16]. While it is true that different conditions may require different techniques, our data show extensive variability even within the same clinical condition.

Simple clinical signs led to FC in more than 80 % patients (hypotension, 58.7 %; oliguria, 18 %; or weaning of vasopressors, 7.1 %). Of note, markers of inadequate tissue perfusion such as lactate or skin mottling were used as an indication for an FC only in less than 8 % of the cases. This seems paradoxical since fluids are mostly indicated to increase cardiac output [11, 17, 18] and tissue perfusion [19]. Moreover, some studies focused on microcirculation clearly showed that clinical signs cannot predict microcirculatory

**Table 2** Fluid challenge ( $N = 2213$ ) characteristics

Volume (ml), median [IQR]	500 [500–999]		
Rate (ml/h), median [IQR]	1000 [500–1333]		
Type of fluids	<i>n</i>	% Of category	% All fluids
Crystalloids	1713		74.3 [72.5–76.1]
NaCl 0.9 %	786	45.9 [43.5–48.3]	34.1 [32.1–36.1]
Balanced	916	53.5 [51.1–55.9]	39.8 [37.8–41.8]
G5 % DW	4	0.2 [0.0–0.4]	0.2 [0.0–0.4]
G5 % NaCl 0.45 %	7	0.4 [0.1–0.7]	0.3 [0.1–0.5]
Colloids	591		25.6 [23.8–27.4]
HES	249	42.1 [38.1–46.1]	10.8 [9.5–12.1]
Albumin 4–5 %	101	17.1 [14.1–20.1]	4.3 [3.5–5.2]
Gelatin	203	34.3 [30.5–38.1]	8.8 [7.6–10.0]
Dextran	13	2.2 [1.0–3.4]	0.5 [0.2–0.8]
Albumin 20 %	25	4.2 [2.6–5.8]	1.1 [0.7–1.5]

*NaCl* saline, *balanced* crystalloids with chloride concentration lower than saline (i.e., Plasma Lyte, Hartman's), *G5 %* glucose 5 %, *DW* dextrose in water, *HES* hydroxyethyl starch

**Table 3** Indications and variables used to predict fluid responsiveness ( $N = 2213$ )

Indication	<i>n</i> (%)		
Hypotension	1211 (58.7 [56.7–60.8])		
Weaning vasopressor	146 (7.1 [6.0–8.2])		
Cardiac output	62 (3.0) [2.3–3.7]		
Oliguria	372 (18.0 [16.4–19.6])		
Skin mottling	36 (1.7 [1.2–2.2])		
Lactate	128 (6.2 [5.2–7.2])		
SvO <sub>2</sub> /ScvO <sub>2</sub>	10 (0.5 [0.2–0.8])		
SVV/PPV	37 (1.8 [1.3–2.4])		
CVP/PAOP	60 (2.9 [2.2–3.6])		
Hemodynamic variable used to predict fluid responsiveness	<i>n</i>	% Of category	% All
No variable used	945		42.7 [40.6–44.8]
Any variable used	1268		57.3 [55.2–59.4]
Static	785		35.5 [33.5–37.5]
CVP	572	89.9 [87.8–92.0]	25.8 [24.0–27.6]
PAOP	31	4.9 [3.4–6.4]	1.4 [0.9–1.9]
GEDVI	33	5.2 [3.6–6.8]	1.5 [1.0–2.0]
Other	149	23.4 [20.4–26.4]	6.7 [5.7–7.8]
Dynamic	483		21.9 [20.2–23.6]
PPV	88	18.2 [14.8–21.6]	4.0 [3.2–4.8]
SVV	88	18.2 [14.8–21.6]	4.0 [3.2–4.8]
PPV + SVV	24	5.0 [3.1–6.9]	1.1 [0.7–1.5]
PLR	238	49.3 [44.8–53.8]	10.7 [9.4–12.0]
Echo variables	45	9.3 [6.7–11.9]	2.0 [1.4–2.6]

SvO<sub>2</sub> mixed venous oxygen saturation, ScvO<sub>2</sub> central venous oxygen saturation, SVV stroke volume variation, PPV pulse pressure variation, CVP central venous pressure, PAOP pulmonary artery

occlusion pressure, GEDVI global end diastolic volume, PLR passive leg raising, Echo echocardiography


impairment [20] and that improving MAP and diuresis is not sufficient for improving patient outcome [21–23].

These findings are in line with the ones published by Boulain and coauthors [24]. In their study, limited to ICUs in France, low blood pressure and low urine output were the most used triggers for fluid administration. The wider scope of our study demonstrates that this is common practice around the globe. It is interesting that so much attention is paid to the blood pressure at the bedside. This variable is the most used both for triggering and assessing the response to an FC. It is possible that the goal

of many clinicians is the one of increasing BP with an FC. On the other hand it is possible that arterial blood pressure was used as a surrogate of cardiac output (CO). This seems common practice despite the known limitations of this variable when used to estimate CO. The increase in arterial pressure during an FC for instance is variable and depends on vascular tone and arterial elastance [25]. In patients increasing their CO in response to fluids, arterial blood pressure increases only in those with high arterial elastance [26, 27]. In summary, while fluids are mostly indicated to increase cardiac output [11, 17, 18] and tissue



**Fig. 1** Further fluid administration post fluid challenge



perfusion [19] and not to just to increase blood pressure, at the bedside clinicians rely heavily on this variable both to predict and assess fluid responsiveness (Table 4).

Importantly, in almost half of the patients no hemodynamic variable was used to predict fluid responsiveness—and if used CVP was used most often. This is interesting considering that the CVP is a poor variable to predict fluid responsiveness [12, 14, 28].

The use of dynamic indices of preload was infrequent in our study. Cyclical changes in stroke volume (stroke volume variation, SVV) and pulse pressure (pulse pressure variation, PPV) during mechanical ventilation have been shown to predict fluid responsiveness with high sensitivity and specificity [29]. However, one of the limitations is that the patient has to be in controlled ventilation with tidal volumes equal to or higher than 8 ml/kg of ideal body weight [30], and with no arrhythmias. It is possible that the limited use of these three dynamic indices (in total 9 % of patients) was influenced by a high prevalence of patients with preserved spontaneous breathing activity. Another possible explanation is that we encouraged investigators to look at the first fluid challenge in our study. In this case flow monitors may have not have been in place yet. In this scenario though, we would have expected a more prevalent use of echocardiography. Of note, this was used to indicate FC in only 2 % of the patients.

Passive leg rising is a maneuver that produces an autologous fluid challenge by shifting venous blood from the legs to the intrathoracic compartment. The response

measured by a flow monitor is able to predict the response to a fluid challenge. This has been studied and validated with different flow monitors. With a lower degree of accuracy with respect to cardiac output and stroke volume, blood pressure monitoring could be used for this technique, too [31]. Considering that an increase in blood pressure was used as the positive indicator of a fluid challenge in two-thirds of the cases, our data suggest that arterial pressure is the hemodynamic variable on which the majority of clinicians focus. Hypotension and weaning of vasopressor were the main indications to give an FC and the response in arterial pressure was the most used one for evaluation of possible benefit.

Our findings highlight a possible safety problem. Half of the patients with a negative response received further fluids. Of note, in three out four cases no safety limits were used at all. While CVP is a poor marker of preload and fluid responsiveness, it is one of the regulating functions of the venous return and a raise in CVP may be used as a safety limit [9, 32–34]. Given this finding and that patients received further fluids despite no response to the initial FC, the current practice and evaluation of FC and fluid administration in critically ill patients seems to be arbitrary, not evidence-based and possibly harmful.

We also found a high variability in the type of fluid used with higher use of crystalloids compared to colloids. It is difficult to interpret these results, since this study was performed during a time of high debate among intensive care clinicians following the publication of large

**Table 4** Judged response to fluid challenge

Response classification [no. (%) of 2162]	
Negative response	429 (19.8 [18.1–21.5])
Positive response	1544 (71.4 [69.5–71.4])
Uncertain	189 (8.7 [7.5–9.9])
Variable use to evaluate response [no. (%) of 1544 with positive response]	
Increase in BP	1039 (67.3 [65.0–69.7])
Decrease vasopressors	56 (3.6 [2.7–4.5])
Increase in CO	174 (11.3 [9.7–12.9])
Increase in SV	100 (6.5 [5.3–7.7])
Decrease in HR	374 (24.2 [22.1–26.3])
Urine output	590 (38.2 [35.8–40.6])
Lactate	281 (18.2 [16.3–20.1])
Skin perfusion	128 (8.3 [6.9–9.7])
Mental state	40 (2.6 [1.8–3.4])
ScvO <sub>2</sub> /SvO <sub>2</sub>	77 (5.0 [3.9–6.1])
SVV/PPV	110 (7.1 [5.8–8.4])
CVP/PAOP	256 (16.6 [14.7–18.5])
Other	132 (8.5 [7.1–9.9])
Safety limit used [no. (%) of 2213]	577 (27.9 [25.7–30.1])
Variable used in the safety limit group [no. (%) of 577]	
CVP	329 (57.0 [53.0–61.0])
PAOP	39 (6.7 [4.7–8.8])
GEDVI	11 (1.9 [4.7–8.8])
EVLWI	28 (4.9 [3.1–6.7])
SpO <sub>2</sub> /SaO <sub>2</sub>	105 (18.2 [15.1–21.35])
CO	8 (1.4 [0.4–2.4])
SVV/PPV	80 (13.9 [11.1–16.7])
Other	120 (20.8 [17.5–24.1])

BP blood pressure, CO cardiac output, SV stroke volume, HR heart rate, SvO<sub>2</sub> mixed venous oxygen saturation, ScvO<sub>2</sub> central venous oxygen saturation, SVV stroke volume variation, PPV pulse pressure variation, CVP central venous pressure, PAOP pulmonary artery occlusion pressure, GEDVI global end diastolic volume, EVLWI extravascular lung water index

randomized controlled trials advocating the use of crystalloids versus colloids [1, 35–38].

Our study has some obvious strengths. First, to the best of our knowledge this study is the largest prospective observational study investigating FCs in critically ill patients and thus provides a reasonably exact estimate of the current practice of the FCs given. Second, the international multicenter design limiting the cases from individual sites increases its external validity. However, there are several limitations of our study to be considered. First, we recorded only when FCs were given and not when FCs were not given. Thus, in practice we may have underestimated the times when variables used to predict fluid responsiveness were used. Second, we encouraged investigators to record data on the first fluid challenge, which may have several implications. At early stages, a positive response to fluids is more likely and patients are often less invasively monitored. Studying patients at later stages may have yielded different results. Third, we allowed a wide range of options (volume, type of fluid, first or subsequent FC) to be recorded during an FC. It is possible that some investigators considered an FC what would be normally defined a more sustained volume expansion.

We conclude that the current practice and evaluation of FC in critically ill patients seems to be arbitrary. While not demonstrable in this observational study, this practice does not seem evidence-based and could be harmful.

Our findings highlight an urgent need for more educational activities and more research to assess whether a more standardized approach to a fluid challenge could lead to better patient-centered outcomes.

**Conflicts of interest** Antonio Artigas is a scientific advisor of B. Braun and Ferrer, received a restricted research grant from Grifols and Pulsion, and is an invited speaker of Grifols. Michael Sander received financial support from Masimo, Pulsion, Edwards Lifesciences, and Maquet. Jean-Louis Teboul is a member of the medical advisory board of Pulsion. The other authors declare no conflict of interest.

**Open Access** This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (<http://creativecommons.org/licenses/by-nc/4.0/>), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.



## References

- Myburgh JA, Mythen MG (2013) Resuscitation fluids. *N Engl J Med* 369:2462–2463
- Hamilton MA, Cecconi M, Rhodes A (2011) A systematic review and meta-analysis on the use of preemptive hemodynamic intervention to improve postoperative outcomes in moderate and high-risk surgical patients. *Anesth Analg* 112:1392–1402
- Cecconi M, Corredor C, Arulkumaran N, Abuello G, Ball J, Grounds RM, Hamilton M, Rhodes A (2013) Clinical review: goal-directed therapy-what is the evidence in surgical patients? The effect on different risk groups. *Crit Care* 17:209
- Cecconi M, De Backer D, Antonelli M, Beale R, Bakker J, Hofer C, Jaeschke R, Mebazaa A, Pinsky MR, Teboul JL, Vincent JL, Rhodes A (2014) Consensus on circulatory shock and hemodynamic monitoring. Task force of the European Society of Intensive Care Medicine. *Intensive Care Med* 40:1795–1815
- Lee SJ, Ramar K, Park JG, Gajic O, Li G, Kashyap R (2014) Increased fluid administration in the first three hours of sepsis resuscitation is associated with reduced mortality: a retrospective cohort study. *Chest* 146:908–915
- Payen D, de Pont AC, Sakr Y, Spies C, Reinhart K, Vincent JL, Sepsis Occurrence In Acutely Ill Patients (SOAP) Investigators (2008) A positive fluid balance is associated with a worse outcome in patients with acute renal failure. *Crit Care* 12:R74
- Vaara ST, Korhonen AM, Kaukonen KM, Nisula S, Inkinen O, Hoppu S, Laurila JJ, Mildh L, Reinikainen M, Lund V, Parviainen I, Pettilä V, Group FS (2012) Fluid overload is associated with an increased risk for 90-day mortality in critically ill patients with renal replacement therapy: data from the prospective FINNAKI study. *Crit Care* 16:R197
- National Heart L, Blood Institute Acute Respiratory Distress Syndrome Clinical Trials N, Wiedemann HP, Wheeler AP, Bernard GR, Thompson BT, Hayden D, deBoisblanc B, Connors AF Jr, Hite RD, Harabin AL (2006) Comparison of two fluid-management strategies in acute lung injury. *N Engl J Med* 354:2564–2575
- Weil MH, Henning RJ (1979) New concepts in the diagnosis and fluid treatment of circulatory shock. Thirteenth annual Becton, Dickinson and Company Oscar Schwidetsky Memorial Lecture. *Anesth Analg* 58:124–132
- Vincent JL, Weil MH (2006) Fluid challenge revisited. *Crit Care Med* 34:1333–1337
- Cecconi M, Parsons AK, Rhodes A (2011) What is a fluid challenge? *Curr Opin Crit Care* 17:290–295
- Marik PE, Baram M, Vahid B (2008) Does central venous pressure predict fluid responsiveness? A systematic review of the literature and the tale of seven maids. *Chest* 134:172–178
- Marik PE, Cavallazzi R, Vasu T, Hirani A (2009) Dynamic changes in arterial waveform derived variables and fluid responsiveness in mechanically ventilated patients: a systematic review of the literature. *Crit Care Med* 37:2642–2647
- Marik PE, Cavallazzi R (2013) Does the central venous pressure predict fluid responsiveness? An updated meta-analysis and a plea for some common sense. *Crit Care Med* 41:1774–1781
- Dellinger RP, Levy MM, Rhodes A, Annane D, Gerlach H, Opal SM, Sevransky JE, Sprung CL, Douglas IS, Jaeschke R, Osborn TM, Nunnally ME, Townsend SR, Reinhart K, Kleinpell RM, Angus DC, Deutschman CS, Machado FR, Rubenfeld GD, Webb S, Beale RJ, Vincent JL, Moreno R, Surviving Sepsis Campaign Guidelines Committee including The Pediatric Subgroup (2013) Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock, 2012. *Intensive Care Med* 39:165–228
- Knott A, Pathak S, McGrath JS, Kennedy R, Horgan A, Mythen M, Carter F, Francis NK (2012) Consensus views on implementation and measurement of enhanced recovery after surgery in England: Delphi study. *BMJ Open*. doi: [10.1136/bmjopen-2012-001878](https://doi.org/10.1136/bmjopen-2012-001878)
- Silva E, De Backer D, Creteur J, Vincent JL (2004) Effects of fluid challenge on gastric mucosal PCO<sub>2</sub> in septic patients. *Intensive Care Med* 30:423–429
- Cecconi M, Reynolds TE, Al-Subaie N, Rhodes A (2007) Haemodynamic monitoring in acute heart failure. *Heart Fail Rev* 12:105–111
- Ospina-Tascon G, Neves AP, Occhipinti G, Donadello K, Buchele G, Simion D, Chierago ML, Silva TO, Fonseca A, Vincent JL, De Backer D (2010) Effects of fluids on microvascular perfusion in patients with severe sepsis. *Intensive Care Med* 36:949–955
- Sakr Y, Dubois MJ, De Backer D, Creteur J, Vincent JL (2004) Persistent microcirculatory alterations are associated with organ failure and death in patients with septic shock. *Crit Care Med* 32:1825–1831
- Rivers E, Nguyen B, Havstad S, Ressler J, Muzzin A, Knoblich B, Peterson E, Tomlanovich M (2001) Early goal-directed therapy in the treatment of severe sepsis and septic shock. *N Engl J Med* 345:1368–1377
- Jansen TC, van Bommel J, Schoonderbeek FJ, Sleswijk Visser SJ, van der Klooster JM, Lima AP, Willemsen SP, Bakker J (2010) Early lactate-guided therapy in intensive care unit patients: a multicenter, open-label, randomized controlled trial. *Am J Respir Crit Care Med* 182:752–761
- Jones AE, Shapiro NI, Trzeciak S, Arnold RC, Claremont HA, Kline JA, Emergency Medicine Shock Research Network I (2010) Lactate clearance vs central venous oxygen saturation as goals of early sepsis therapy: a randomized clinical trial. *JAMA* 303:739–746
- Boulain T, Boissrame-Helms J, Ehrmann S, Lascarrou JB, Bougle A, Chiche A, Lakhal K, Gaudry S, Perbet S, Desachy A, Cabasson S, Geneau I, Courouble P, Clavieres N, Massanet PL, Bellec F, Falquet Y, Reminiac F, Vignon P, Dequin PF, Meziani F (2015) Volume expansion in the first 4 days of shock: a prospective multicentre study in 19 French intensive care units. *Intensive Care Med* 41:248–256
- Pierrakos C, Velissaris D, Scolletta S, Heenen S, De Backer D, Vincent JL (2012) Can changes in arterial pressure be used to detect changes in cardiac index during fluid challenge in patients with septic shock? *Intensive Care Med* 38:422–428
- Cecconi M, Monge Garcia MI, Gracia Romero M, Mellinshoff J, Caliendo F, Grounds RM, Rhodes A (2014) The use of pulse pressure variation and stroke volume variation in spontaneously breathing patients to assess dynamic arterial elastance and to predict arterial pressure response to fluid administration. *Anesth Analg* 120:76–84
- Monge Garcia MI, Gil Cano A, Gracia Romero M (2011) Dynamic arterial elastance to predict arterial pressure response to volume loading in preload-dependent patients. *Crit Care* 15:R15
- Cecconi M, Aya HD (2014) Central venous pressure cannot predict fluid-responsiveness. *Evid Based Med* 19:63

29. Monnet X, Teboul JL (2013) Assessment of volume responsiveness during mechanical ventilation: recent advances. *Crit Care* 17:217
30. De Backer D, Heenen S, Piagnerelli M, Koch M, Vincent JL (2005) Pulse pressure variations to predict fluid responsiveness: influence of tidal volume. *Intensive Care Med* 31:517–523
31. Monnet X, Rienzo M, Osman D, Anguel N, Richard C, Pinsky MR, Teboul JL (2006) Passive leg raising predicts fluid responsiveness in the critically ill. *Crit Care Med* 34:1402–1407
32. Cecconi M, Aya HD, Geisen M, Ebm C, Fletcher N, Grounds RM, Rhodes A (2013) Changes in the mean systemic filling pressure during a fluid challenge in postsurgical intensive care patients. *Intensive Care Med* 39:1299–1305
33. Guyton AC, Richardson TQ, Langston JB (1964) Regulation of cardiac output and venous return. *Clin Anesth* 3:1–34
34. Berlin DA, Bakker J (2014) Understanding venous return. *Intensive Care Med* 40:1564–1566
35. Gattas DJ, Dan A, Myburgh J, Billot L, Lo S, Finfer S (2013) Fluid resuscitation with 6% hydroxyethyl starch (130/0.4 and 130/0.42) in acutely ill patients: systematic review of effects on mortality and treatment with renal replacement therapy. *Intensive Care Med* 39:558–568
36. Myburgh JA, Finfer S, Bellomo R, Billot L, Cass A, Gattas D, Glass P, Lipman J, Liu B, McArthur C, McGuinness S, Rajbhandari D, Taylor CB, Webb SA (2012) Hydroxyethyl starch or saline for fluid resuscitation in intensive care. *N Engl J Med* 367:1901–1911
37. Perner A, Haase N, Guttormsen AB, Tenhunen J, Klemenzson G, Aneman A, Madsen KR, Moller MH, Elkjaer JM, Poulsen LM, Bendtsen A, Winding R, Steensen M, Berezowicz P, Soe-Jensen P, Bestle M, Strand K, Wiis J, White JO, Thornberg KJ, Quist L, Nielsen J, Andersen LH, Holst LB, Thormar K, Kjaeldgaard AL, Fabritius ML, Mondrup F, Pott FC, Moller TP, Winkel P, Wetterslev J (2012) Hydroxyethyl starch 130/0.42 versus Ringer's acetate in severe sepsis. *N Engl J Med* 367:124–134
38. Reinhart K, Perner A, Sprung CL, Jaeschke R, Schortgen F, Johan Groeneveld AB, Beale R, Hartog CS (2012) Consensus statement of the ESICM task force on colloid volume therapy in critically ill patients. *Intensive Care Med* 38:368–383